News
April 9, 2010
There were an estimated 440,000 cases of multidrug-resistant tuberculosis (MDR-TB) around the world in 2008 – one-third of which were fatal, according to a new WHO report on drug-resistant TB, the Los Angeles Times reports (Maugh, 3/19). The WHO report, based on data from 2008, found that almost half of all drug-resistant TB cases were in China and India, Reuters reports (Fox, 3/18).
April 9, 2010
Tuberculosis (TB) will be eradicated from Sri Lanka by 2025, twenty five years ahead of the target set by the WHO which is 2050. Sri Lanka's TB Control program will cover the whole country when the 26th Chest Clinic will commence operations in Mulaitivu shortly, a Healthcare and Nutrition Ministry spokesman said.
April 9, 2010
Johns Hopkins University scientists say they have identified a class of compounds that, in a test tube, can block the growth of tuberculosis bacteria.
April 9, 2010
The U.S. Food and Drug Administration is changing rules for testing tuberculosis drugs to enable Johnson & Johnson, Sanofi-Aventis SA and Pfizer Inc. to speed up approval of new combination treatments by decades.
April 9, 2010
Researchers at Albert Einstein College of Medicine of Yeshiva University have found two novel ways of killing the bacteria that cause tuberculosis.
April 9, 2010
In some areas of the world, one in four people with tuberculosis (TB) becomes ill with a resistant form of the disease that can no longer be treated with standard drug regimens, a World Health Organization (WHO) report says. The report reveals that in one region of north-western Russia 28 of all people newly diagnosed with TB had the multidrug-resistant form of the disease (MDR-TB) in 2008. This is the highest level ever reported.. Previously, the highest recorded level was 22% in Baku City, Azerbaijan, in 2007.
April 9, 2010
Two research teams, the British one at the Center and colleagues at the Yeshiva University Albert Einstein College of Medicine, in the United States, reached the new pathway of attack independent from each other, by using different methods. They found that an enzyme called GlgE played an important part in the TB cells, by clearing them of a modified sugar called maltose 1-phosphate.
April 9, 2010
Global tuberculosis therapeutics market is expected to exceed US$846 million by 2015. Outbreak of TB-HIV co-infections, emergence of MDR- and XDR- TB strains, and widespread disease prevalence in high burden regions such as Africa and Asia, where case detection rates are critically low posing significant challenge for the control of this disease, all indicate high unmet needs in diagnosis and treatment.
April 9, 2010
Strathclyde University scientists have remolded the structure of an antibiotic known as thiolactomycin (TLM) to generate a compound which acts against Mycobacterium tuberculosis.
March 18, 2010
A study into why some people are more resistant than others to diseases such as tuberculosis (TB) and leprosy has identified a new genetic variant which affects susceptibility to these diseases. The findings, published today in the journal Cell, may have implications for future treatments for the two conditions.
March 18, 2010
In a landmark study that could provide new pathways for Tuberculosis (TB) therapy, Indian scientists have unlocked the secret formula that the TB bacterium uses to survive inside the human body. The results could be used to create a novel TB therapy, one that isn't antibiotics-based and could be a valuable tool in the fight against antibiotic-resistant TB.
March 18, 2010
Initiating antiretroviral therapy (ART) during tuberculosis therapy significantly reduced mortality rates by 56 percent in a randomized clinical trial of 642 patients co-infected with HIV and tuberculosis. The study, which provides further impetus for the integration of TB and HIV services, lays to rest the controversy on whether co-infected patients should initiate ART during or after TB treatment.
March 18, 2010
Initiating antiretroviral therapy (ART) during tuberculosis therapy significantly reduced mortality rates by 56 percent in a randomized clinical trial of 642 patients co-infected with HIV and tuberculosis. The study, which provides further impetus for the integration of TB and HIV services, lays to rest the controversy on whether co-infected patients should initiate ART during or after TB treatment.
March 18, 2010
"The breath test appears to detect volatile organic compounds manufactured by the infecting organism, Mycobacterium tuberculosis, that causes the disease. The breath test detects a signal from Mycobacteria in the lungs, which is why it's probably a better test than skin tests or a blood test for tuberculosis that measure the body's immune response to infection."
March 18, 2010
Researcher's aim for this article is to review briefly the problems related to treatment of drug-susceptible and drug-resistant tuberculosis (TB), describe recent advances in the development of new drugs and new regimens, and discuss implications for control programmes.
March 18, 2010
The FDA is drafting new guidelines for testing and approving multidrug cocktails for life-threatening diseases, such as TB, AIDS, cancer, etc.
February 19, 2010
Investigators from Dartmouth Medical School (DMS) have reported results of a clinical trial showing that a new vaccine against tuberculosis, Mycobacterium vaccae (MV), is 39 effective in preventing tuberculosis in people with HIV infection.
February 19, 2010
"The resurgence of tuberculosis is not limited to South Africa. India and China have the largest numbers of tuberculosis cases, and multi-drug-resistant tuberculosis (MDR-TB) has been found in nearly every country, with XDR [extensively drug resistant]-TB in at least 57 countries.
February 19, 2010
Adherence to internationally agreed standards of care and control practices is imperative to achieve TB control.
February 19, 2010
South African pharmaceutical company Aspen Pharmacare announced that it plans to begin manufacturing the drug capreomycin to treat extensively drug-resistant tuberculosis.
Displaying 1 through 20 of 836 items.
